<DOC>
	<DOCNO>NCT00434213</DOCNO>
	<brief_summary>This study design characterize dermal response DAYTRANA . Subjects visit study site period approximately 14 week .</brief_summary>
	<brief_title>Characterization Dermal Reactions Pediatric Patients With ADHD Using DAYTRANA</brief_title>
	<detailed_description>This study design characterize dermal response DAYTRANA . Subjects visit study site period approximately 14 week . Subjects titrate optimum dose study treatment assess safety efficacy . Dermal response evaluate visit investigator . Subjects high dermal response score score persist application site improvement 4 evaluation ( exceed two week period ) discontinue study refer study specific dermatologist specialize skin sensitivity skin patch testing .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Must sign inform consent . Male female 612 year old . Negative pregnancy test . Meet Diagnostic Statistical Manual Mental Disorders , 4th edition Text Revision ( DSMIVTR ) criteria primary diagnosis ADHD . No comorbid illness could affect safety , tolerability interfere participation . Blood pressure ( BP ) within 95th percentile age , gender , height . Willing able comply requirement define protocol . Current control ( require restrict medication ) uncontrolled comorbid psychiatric diagnosis ( except Oppositional Defiant Disorder [ ODD ] ) . At risk suicidal violent behavior towards self others . History suicide attempt . History structural cardiac abnormality serious cardiac problem . Nonresponder psychostimulant treatment . Is overweight . Seizures last 2 year ( exclusive infantile febrile seizure ) , tic disorder , current diagnosis and/or family history Tourette 's Disorder . Has Conduct Disorder . Known history alcohol substance abuse within last 6 month . Any abnormal thyroid function . A concurrent chronic acute illness , disability , condition might confound result safety assessment . Has treatment know liver alter agent within 30 day prior Screening . Taking excluded medication . Previous use DAYTRANA . Taking medication Central Nervous System ( CNS ) effect . Female subject pregnant lactating . Has skin disease , history chronic skin disease , skin cancer , skin manifestation allergic disease , dermatologic condition . Has sensitiveskin syndrome sensitivity ingredient soap , lotion , cosmetic adhesive . Has clinical sign symptom skin irritation hyper/hypopigmentation potential application site . A documented allergy , hypersensitivity intolerance methylphenidate ( MPH ) component find DAYTRANA .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>